Navigation Links
Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results
Date:11/9/2011

at could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review and approval is uncertain; regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than we or others do, request additional information, have additional recommendations or change their guidance or requirements before or after approval; the risk that data and other information related to Arena's research and development programs may not meet safety or efficacy requirements or otherwise be sufficient for regulatory approval; Arena's response to the CRL for the lorcaserin NDA or submission of a Marketing Authorization Application for regulatory approval of lorcaserin may not be submitted when anticipated, if at all; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Arena
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
2. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
3. Arena Pharmaceuticals Announces Second Quarter 2011 Financial Results
4. Arena and Eisai Announce Results of Re-Adjudication of Rat Mammary Tumors from Lorcaserin Carcinogenicity Study
5. Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses
6. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
7. Arena Pharmaceuticals Announces Phase 1 Results for APD811 for Pulmonary Arterial Hypertension
8. Meta-Analyses of Phase 3 Trials Show Obese and Overweight Patients Taking Arena Pharmaceuticals Lorcaserin Achieved Statistically Significant Weight Loss
9. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
10. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
11. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, May 10
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , June 29, 2015 ... addition of the "Pharmaceutical Grade Sodium Chloride Market ... to 2019" report to their offering. ... witness a CAGR of 6.9% between 2014 and 2019 ... to reach 690 KT by 2019. The ...
(Date:7/6/2015)... BOULDER, Colo. , July 6, 2015 /PRNewswire/ ... inhibitor, encorafenib, was showcased this past weekend at ... during an oral presentation.  At the meeting, data ... preliminary data from a 100-patient randomized Phase 2 ... encorafenib and cetuximab, an EGFR inhibitor, with or ...
(Date:7/6/2015)...   Cepheid (Nasdaq: CPHD ) today announced ... second quarter ended June 30, 2015 on Thursday, July ... The Company will host a management presentation at ... to discuss the results.  To access the live webcast, ... least 15 minutes before the scheduled start time to ...
Breaking Medicine Technology:Global Pharmaceutical Grade Sodium Chloride Market Report 2015 2Global Pharmaceutical Grade Sodium Chloride Market Report 2015 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 2Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 3Encorafenib-Based Regimens Show Promising Clinical Activity In BRAF-Mutant Colorectal Cancer Patients 4
... mental retardation, birth defects, and autism spectrum and ... in New YorkMADISON, N.J., March 17 Quest ... world,s leading provider of diagnostic testing, information and ... genomic hybridization (aCGH) postnatal test is now available ...
... Inc. announced today that it has achieved proof ... Inhibiting Multiple Pathways) kinase platform by designing a ... of both the PI3K (Phosphoinositide-3-kinase) pathway and the ... SF2626 has demonstrated the ability to inhibit both ...
Cached Medicine Technology:Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State 2Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State 3Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State 4Semafore Achieves a Preclinical Milestone with SF2626, a PI3K-MEK Dual Pathway Kinase Inhibitor 2
(Date:7/6/2015)... ... July 06, 2015 , ... Cancer Hope Network (CHN) has ... medical professionals to chat with the CHN patient services team and connect with ... diagnosis is often the most traumatic experience of a person’s life,” said CHN ...
(Date:7/6/2015)... ... July 06, 2015 , ... ... & Associates has once again teamed up with Family Emergency Shelter Coalition (FESCO) ... move toward self-sufficiency. FESCO was created especially to provide emergency services and support ...
(Date:7/6/2015)... ... 06, 2015 , ... With a new community program in the Livonia, Canton ... and announced a new charity campaign to raise funds in support of the health ... Livonia Save Our Youth is a coalition created especially to educate and empower teens, ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... Dr. Lawrence ... Washington, DC, area patients. Kybella is a non-surgical method to dissolve fat ... of reducing moderate to severe fat deposits under the chin, commonly known as a ...
(Date:7/6/2015)... Kingdom (PRWEB) , ... July 06, 2015 , ... Diabetes ... could help. More than 29 million Americans have diabetes, the majority of which are ... million U.S. adults or more than one in three, have prediabetes (abnormally high blood ...
Breaking Medicine News(10 mins):Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 3Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 2Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 3Health News:Rockville, MD Practice Now Offering New FDA-Approved Non-Surgical Double Chin Treatment 2Health News:115 Million in the U.S. could beat diabetes with the help of a new app 2
... people "tear up," but a new study led by University of ... containing an ingredient derived from hot chili peppers ( Capsicum annum ... The study, which appears in the August 2011 edition ... use of the Capsicum annum nasal spray to a ...
... cyclase C (GCC) has been established as a suppressor ... Thomas Jefferson University suggests it may also help ... Reporting in the August 25 online issue of ... M.D., Ph.D., chairman of the Department of Pharmacology ...
... HealthDay Reporter , THURSDAY, Aug. 25 (HealthDay News) -- An ... finds that children,s vaccines are typically safe, with bad reactions ... problems. The IOM committee also agreed that there is ... later onset of conditions such as autism or type 1 ...
... Aug. 24, 2011 -- Heart rate and blood pressure ... in children. In a new study by researchers at Wake ... a condition known as orthostatic intolerance (OI), which causes dizziness ... shown to reduce debilitating chronic nausea in patients., "There seems ...
... , WASHINGTON An analysis of more than 1,000 ... by or clearly associated with vaccines. A committee ... review the scientific literature on possible adverse effects of ... including seizures, inflammation of the brain, and fainting -- ...
... THURSDAY, Aug. 25 (HealthDay News) -- Federal officials on Thursday ... make emergency preparations for Hurricane Irene, a "category 3" storm ... current forecast places the center of Irene just off the ... Monday morning, according to the U.S. National Weather Service. ...
Cached Medicine News:Health News:Could a tumor suppressor also fight obesity? 2Health News:U.S.-Mandated Report Finds Vaccines Safe for Kids 2Health News:U.S.-Mandated Report Finds Vaccines Safe for Kids 3Health News:U.S.-Mandated Report Finds Vaccines Safe for Kids 4Health News:Heart may hold key to unexplained nausea in youths 2Health News:Few health problems are caused by vaccines, IOM report finds 2Health News:Few health problems are caused by vaccines, IOM report finds 3Health News:East Coast Urged to Prepare as Hurricane Irene Approaches 2
White Standard Girdle...
Below Knee Girdle, High Waist...
Bodyshaper For Men...
Torso Brief Bodysuit V-BA85...
Medicine Products: